Abstract
E069 Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have